Akoya Biosciences, INC

Akoya Biosciences, Inc. has completed its merger with Wellfleet Merger Sub, Inc., a wholly-owned subsidiary of Quanterix Corporation, resulting in Akoya becoming a wholly-owned subsidiary of Quanterix.

Akoya Biosciences, Inc. stockholders overwhelmingly approved the proposed merger with Quanterix Corporation at a special meeting held on July 7, 2025.

Akoya Biosciences announced that Party A has withdrawn its unsolicited all-cash acquisition proposal, with Akoya's board reaffirming its commitment to the previously announced merger with Quanterix Corporation.

Akoya Biosciences received an unsolicited all-cash acquisition proposal of $1.40 per share from a third party while already in a merger agreement with Quanterix.

Akoya Biosciences announced its Q1 2025 financial results, highlighting revenue of $16.6 million and progress in spatial biology adoption, while also noting a pending acquisition by Quanterix Corporation.

Quanterix and Akoya Biosciences have amended their merger agreement, reducing the number of Quanterix shares to be issued and adding a cash component for Akoya shareholders.

Akoya Biosciences announces its Q1 2025 financial results, showing a net loss but also highlighting its ongoing merger agreement with Quanterix.

Akoya Biosciences' Q3 2024 results show a decrease in revenue and a net loss, alongside restructuring and cost-saving initiatives.

Akoya Biosciences experienced a decrease in revenue and a net loss for the second quarter of 2024, while implementing cost-saving initiatives including a workforce reduction and facility consolidation.

Akoya Biosciences' first quarter 2024 results show a decrease in revenue and a net loss, impacted by lower instrument sales and restructuring costs.

Akoya Biosciences files an amendment to its 2024 Annual Report on Form 10-K to include information required by Part III, covering directors, executive officers, compensation, and corporate governance.

Akoya Biosciences reports a net loss for 2024 but highlights its leading position in the spatial biology market and a pending merger with Quanterix.

Akoya Biosciences, a leader in spatial biology, announced its full year 2023 results, showcasing a 29% revenue increase and a 27% expansion of its installed instrument base.

Akoya Biosciences Director Scott Mendel reported the disposition of all his common stock and stock options in Akoya Biosciences, Inc. on July 8, 2025, as a result of the company's merger with Quanterix Corporation.

Akoya Biosciences, Inc. Chief Business Officer, Niro Ramachandran, Ph.D., converted his equity holdings into Quanterix Corporation shares and cash following the merger of Akoya into a wholly-owned subsidiary of Quanterix.

Akoya Biosciences, Inc. President and CEO Brian McKelligon reported the final disposition of his common stock and derivative securities in Akoya Biosciences following its merger with Quanterix Corporation on July 8, 2025.

Jennifer Kamocsay, Chief Legal Officer of Akoya Biosciences, Inc., reported the disposition of common stock and employee stock options as Akoya Biosciences merged into a wholly-owned subsidiary of Quanterix Corporation on July 8, 2025.

Akoya Biosciences, Inc. CFO John Frederick Ek has reported the complete disposition of his beneficial ownership in Akoya common stock and stock options, effective July 8, 2025, as a result of the company's merger with Quanterix Corporation.

Akoya Biosciences' Chief Clinical Officer, Pascal Bamford, reported the disposition of common stock and termination of stock options and conversion of restricted stock units as a result of the company's merger with Quanterix Corporation on July 8, 2025.

Quanterix Corporation and Akoya Biosciences, Inc. have announced an amended merger agreement, where Akoya shareholders will receive a mix of Quanterix stock and cash, aiming to create a fully integrated technology ecosystem for biomarker detection.

Quanterix Corporation will acquire Akoya Biosciences, Inc. in an all-stock transaction, pending stockholder and regulatory approvals.

Akoya Biosciences announces its 2024 Annual Meeting of Stockholders to be held on June 4, 2024, featuring the election of directors and ratification of the company's accounting firm.

Akoya Biosciences announces its 2024 Annual Meeting of Stockholders to be held on June 4, 2024, featuring proposals for director elections and ratification of the company's accounting firm.

Akoya Biosciences, Inc. has terminated its Voting and Support Agreement with certain Quanterix Corp. stockholders, a procedural step following the execution of an Amended and Restated Agreement and Plan of Merger.

Quanterix Corporation has amended its merger agreement with Akoya Biosciences, Inc., outlining revised acquisition terms and securing voting support from key Akoya shareholders representing 55.6% of outstanding common stock.

Quanterix Corporation has entered into a definitive agreement to acquire Akoya Biosciences, Inc. through a merger, with Akoya becoming a wholly-owned subsidiary of Quanterix, significantly altering the combined entity's ownership structure and board composition.

Quanterix Corporation has entered into a definitive agreement to acquire Akoya Biosciences, Inc. in an all-stock transaction, with Akoya becoming a wholly-owned subsidiary of Quanterix.